Page last updated: 2024-08-21

arsenic trioxide and Local Neoplasm Recurrence

arsenic trioxide has been researched along with Local Neoplasm Recurrence in 57 studies

Research

Studies (57)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.75)	18.2507
2000's	21 (36.84)	29.6817
2010's	28 (49.12)	24.3611
2020's	7 (12.28)	2.80

Authors

Authors	Studies
Chen, X; Feng, J; Hong, Y; Huang, Z; Wang, Y; You, X; Zheng, P	1
Stahl, M; Tallman, MS	1
Abraham, A; Alex, AA; Balasubramanian, P; Balasundaram, N; David, S; Devasia, A; Ganesan, S; George, B; Janet, NB; Jeyaseelan, L; Korula, A; Kulkarni, U; Mathews, V; Palani, H; Thenmozhi, M; Venkatraman, A	1
Breccia, M	1
Abraham, A; Balasubramanian, P; Balasundaram, N; David, S; Devasia, AJ; Fouzia, NA; Ganesan, S; George, B; Janet, NB; Korula, A; Kulkarni, UP; Lakshmanan, J; Mani, T; Mathews, V; Nair, SC; Palani, HK; Sharma, V	1
Chen, H; Fan, S; Gao, Y; Guo, M; Hai, X; Lin, L; Wu, Z; Zhao, Q	1
Arena, V; Diverio, D; Foà, R; Ladogana, S; Lo Nigro, L; Locatelli, F; Masetti, R; Menna, G; Micalizzi, C; Micheletti, MV; Mohamed, S; Onofrillo, D; Piciocchi, A; Pierani, P; Putti, C; Rizzari, C; Santoro, N; Testi, AM; Timeus, F; Zecca, M; Ziino, O	1
Bi, Y; Chen, H; Fang, S; Hu, S; Kou, J; Li, T; Ma, R; Mo, H; Novakovic, VA; Shi, J; Wang, J; Wang, L; Yang, X; Yu, B; Zhang, Y; Zhou, J	1
Au, WY; Chan, TSY; Gill, H; Hwang, YY; Ip, HW; Kho, B; Kumana, CR; Kwong, YL; Lau, JSM; Lee, HKK; Li, W; Lin, SY; Mak, V; Tse, E; Yim, R; Yip, SF	1
Betteridge, S; Burnett, A; Dennis, M; Dillon, R; Grimwade, D; Hills, R; Jovanovic, J; Russell, N	1
Bureta, C; Komiya, S; Maeda, S; Nagano, S; Saitoh, Y; Sasaki, H; Setoguchi, T; Taniguchi, N; Tokumoto, H	1
Cai, H; Li, X; Wang, J	1
Atsuta, Y; Emi, N; Fujimaki, K; Fujisawa, S; Fujita, H; Kobayashi, Y; Maeda, A; Miyazaki, Y; Naoe, T; Ohtake, S; Ohwada, A; Sunami, K; Takeshita, A; Taniwaki, M; Tsuboi, K; Tsuzuki, M; Yanada, M	1
Chen, M; Liu, T; Niu, T; Wang, L; Xie, LP; Zeng, K; Zou, XL	1
Chen, Z; Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Suo, S; Tong, H; Tong, Y; Wang, Y; Ye, X	1
Hofmann, WK; Lengfelder, E; Nowak, D	1
Foley, SB; Hildenbrand, ZL; Mgbemena, VE; Oravecz-Wilson, KI; Philips, ST; Ross, TS	1
Ao, JY; Bu, Y; Chai, ZT; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Zhang, KZ; Zhang, QB; Zhang, YY; Zhu, XD	1
Chen, S; Chen, Z; Hu, J; Li, J; Mi, J; Wang, Z; Zhu, H	1
Fang, ZG; He, Y; Hu, Y; Huang, RW; Li, XD; Lin, DJ; Liu, JJ; Liu, Q; Long, ZJ; Wang, DN; Xiao, RZ; Yan, JS	1
Aznab, M; Rezaei, M	1
Boehme, KA; Handgretinger, R; Hopp, U; Kluba, T; Riester, R; Schleicher, SB; Schweiss, SK; Traub, F; Zaborski, JJ	1
Bashford, J; Bradstock, K; Browett, P; Campbell, LJ; Catalano, A; Collins, M; Di Iulio, J; Filshie, R; Firkin, F; Grigg, A; Hertzberg, M; Hugman, A; Iland, HJ; Moore, J; Reynolds, J; Seldon, M; Seymour, JF; Supple, SG; Szer, J; Taper, J; Taylor, K; Tiley, C	1
Blondeau, S; Bouyer, S; Colin, O; Houeto, JL; Julian, A; Meurin, E; Neau, JP; Puyade, M	1
Bechara, R; Chen, Z; Deng, X; Khuri, FR; Kim, HS; Owonikoko, TK; Pakkala, S; Pillai, R; Ramalingam, SS; Rossi, MR; Saba, NF; Sica, GL; Stinson, RM; Sun, SY; Zhang, C; Zhang, G	1
Afroze, D; Azad, NA; Aziz, SA; Baba, SM; Dar, FA; Jan, A; Pandith, AA; Shah, ZA	1
Akiyama, H; Hiruma, K; Jinta, M; Ohashi, K; Okuyama, Y; Sakamaki, H; Ueki, T	1
Aklilu, M; Kindler, HL; Nattam, S; Vokes, EE	1
Altman, JK; Tallman, MS	1
Illmer, T; Röllig, C	1
Angell, R; Aslett, H; Batson, E; Burnett, AK; Clark, RE; Diverio, D; Flora, R; Grimwade, D; Hills, RK; Jones, K; Jovanovic, JV; Lo-Coco, F; Nugent, EA; Patel, Y; Rennie, K; Solomon, E; Wheatley, K	1
Arceci, R; Dauses, T; Devetten, M; Gallagher, RE; Gojo, I; Gore, SD; Jamieson, K; Morris, L; Owoeye, I; Redner, RL; Schachter-Tokarz, E; Sekeres, MA	1
Brûlé, AO; Coser, PL; Coser, VM; Lafayette, TC; Pereira, WV	1
Crocker, IR; Curran, WJ; McDonald, MW; Shu, HK	1
Ardalan, B; Francheschi, D; Livingstone, A; Oh, M; Podolsky, L; Subbarayan, PR	1
Gong, YP; Luo, S; Yang, L; Yang, YM	1
Alimoghaddam, K; Ghaffari, H; Ghavamzadeh, A; Hosseini, R; Iravani, M; Jahani, M; Jalili, M; Mousavi, A; Rostami, S	1
Alimoghaddam, K; Ghaffari, SH; Ghavamzadeh, A; Hajhashemi, M; Mozdarani, H; Yaghmaie, M	1
Atsumi, A; Goto, E; Hayakawa, F; Kiyoi, H; Naoe, T; Tomita, A	1
Hatta, Y; Hirabayashi, Y; Horikoshi, A; Iriyama, N; Takeuchi, J; Toyoda, H; Yoshino, Y; Yuan, B	1
Anaissie, E; Badros, A; Barlogie, B; Desikan, R; Morris, C; Munshi, NC; Toor, A; Tricot, G; Zangari, M	1
Bahlis, NJ; Boise, LH; Eckman, J; Fernandez, HF; Goodman, M; Jordan-McMurry, I; Kharfan-Dabaja, M; Lee, KP; McCafferty-Grad, J; Neil, J; Reis, I	1
Cortes, J; Estey, E; Kantarjian, H; Lazo, G; O'Brien, S; Thomas, D	1
Takeshita, A	1
Ravandi, F	1
Arnulf, B; Chevret, S; Cimerman, P; Claude Brouet, J; Dombret, H; Hermine, O; Larghero, J; Madelaine-Chambrin, I; Paul Fermand, J; Poupon, J; Rousselot, P; Royer, B; Tibi, A	1
Aghdami, N; Alimoghaddam, K; Bahar, B; Baybordi, E; Ghaffari, SH; Ghavamzadeh, A; Hosseini, R; Iravani, M; Jahani, M; Khodabadeh, A; Mortazavi, Y; Mossavi, A; Rostami, S; Totonchi, M	1
Fukuda, M	1
Aribi, A; Cortes, JE; Estey, EH; Faderl, SH; Garcia-Manero, G; Kantarjian, HM; Koller, CA; Kornblau, SM; Laddie, NM; Thomas, DA	1
Tallman, MS	1
Ahn, HS; Kang, HJ; Park, JA; Shin, HY; Yun, JH	1
Jin, Z; Man, Z; Ran, M	1
Hayashi, T; Imanaka, T; Ishii, K; Komatsu, H; Nakamura, F; Ono, Y; Sawada, H; Tanaka, Y	1
Firkin, F; Spencer, A	1
Soignet, SL	1
Rust, DM; Soignet, SL	1
Hu, J; Li, X; Shen, Z; Sun, G; Sun, H; Wang, Z; Wu, W	1

Reviews

9 review(s) available for arsenic trioxide and Local Neoplasm Recurrence

Article	Year
Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all. Leukemia & lymphoma, 2019, Volume: 60, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Disease-Free Survival; Hemorrhage; Humans; Incidence; Leukemia, Promyelocytic, Acute; Mortality; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Remission Induction; Standard of Care; Time Factors; Tretinoin	2019
Arsenic trioxide in the treatment of platinum-resistant recurrent endometrial cancer: a case report and literature review. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2020, Volume: 40, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Arsenic Trioxide; Endometrial Neoplasms; Female; Humans; Neoplasm Recurrence, Local	2020
Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions. Expert review of anticancer therapy, 2013, Volume: 13, Issue:9 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Remission Induction	2013
Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction. International journal of hematology, 2014, Volume: 100, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Salvage Therapy; Tretinoin	2014
The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review. Cancer treatment reviews, 2009, Volume: 35, Issue:5 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oxides; Treatment Outcome	2009
[Recent advances in the treatment of acute myelogenous leukemia: a view of the new agents]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2003, Volume: 44, Issue:12 Topics: Alkyl and Aryl Transferases; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Cyclosporine; Cytarabine; Daunorubicin; Drug Design; Farnesyltranstransferase; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Nucleosides; Oxides; Prognosis; Radioisotopes; Remission Induction; Tetrahydronaphthalenes; Topoisomerase Inhibitors; Tretinoin; Verapamil	2003
Treatment of relapsed or refractory acute promyelocytic leukemia. Best practice & research. Clinical haematology, 2007, Volume: 20, Issue:1 Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Oxides; Transplantation, Autologous; Transplantation, Homologous	2007
Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. The oncologist, 2001, Volume: 6 Suppl 2 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides	2001
Risk/benefit profile of arsenic trioxide. The oncologist, 2001, Volume: 6 Suppl 2 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Risk Assessment	2001

Trials

12 trial(s) available for arsenic trioxide and Local Neoplasm Recurrence

Article	Year
The economic research of arsenic trioxide for the treatment of newly diagnosed acute promyelocytic leukemia in China. Cancer, 2020, 01-15, Volume: 126, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; China; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Female; Hospitalization; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Markov Chains; Middle Aged; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Remission Induction; Treatment Failure; Tretinoin	2020
A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide. Cancer medicine, 2020, Volume: 9, Issue:8 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Biomarkers, Tumor; Bortezomib; Disease Management; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Non-Randomized Controlled Trials as Topic; Prognosis; Salvage Therapy; Survival Rate; Tumor Cells, Cultured; Young Adult	2020
Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial. Blood, 2018, 09-27, Volume: 132, Issue:13 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Tretinoin; Young Adult	2018
Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood, 2013, Apr-18, Volume: 121, Issue:16 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Oxides; Remission Induction; Transcription, Genetic; Transplantation, Autologous; Young Adult	2013
Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy. Leukemia research, 2013, Volume: 37, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxides; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Translocation, Genetic; Tretinoin; Young Adult	2013
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. The Lancet. Haematology, 2015, Volume: 2, Issue:9 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Australia; Consolidation Chemotherapy; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Treatment Outcome; Young Adult	2015
Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. Journal of translational medicine, 2016, 05-03, Volume: 14, Issue:1 Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cisplatin; Electrophoresis; Female; Humans; Lung Neoplasms; Male; Mice, SCID; Middle Aged; Neoplasm Recurrence, Local; Oxides; Small Cell Lung Carcinoma; Subcutaneous Tissue; Treatment Outcome; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2016
Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium. American journal of clinical oncology, 2008, Volume: 31, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Pancreatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome	2008
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-20, Volume: 28, Issue:6 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxides; Prognosis; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin; Young Adult	2010
Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia, 2002, Volume: 16, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Evaluation; Humans; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Oxides; Salvage Therapy; Treatment Outcome	2002
Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Drug Resistance, Neoplasm; Feasibility Studies; Female; Glutathione; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oxides; Salvage Therapy; Treatment Outcome	2002
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer, 2003, May-01, Volume: 97, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Remission Induction; Safety; Salvage Therapy; Survival Rate; Treatment Outcome	2003

Other Studies

36 other study(ies) available for arsenic trioxide and Local Neoplasm Recurrence

Article	Year
Autologous stem cell transplantation finds a place in acute promyelocytic leukaemia. British journal of haematology, 2021, Volume: 192, Issue:2 Topics: Arsenic Trioxide; Arsenicals; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Transplantation, Autologous; Tretinoin	2021
Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens. British journal of haematology, 2021, Volume: 192, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Child; Child, Preschool; Disease Management; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Treatment Outcome; Young Adult	2021
Characteristics of arsenic species in cerebrospinal fluid (CSF) of acute promyelocytic leukaemia (APL) patients treated with arsenic trioxide plus mannitol. British journal of clinical pharmacology, 2021, Volume: 87, Issue:10 Topics: Arsenic; Arsenic Trioxide; Chromatography, High Pressure Liquid; Humans; Leukemia, Promyelocytic, Acute; Mannitol; Neoplasm Recurrence, Local	2021
Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients - a 25-year Italian experience. British journal of haematology, 2021, Volume: 195, Issue:2 Topics: Adolescent; Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Immunological; Arsenic Trioxide; Case-Control Studies; Child; Child, Preschool; Combined Modality Therapy; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Italy; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Prognosis; Progression-Free Survival; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult	2021
Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy. Cell death & disease, 2018, 01-23, Volume: 9, Issue:2 Topics: Adolescent; Adult; Animals; Apoptosis; Arsenic Trioxide; Autophagy; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Mice, SCID; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Reactive Oxygen Species; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tumor Burden; Young Adult	2018
Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study. Cancer, 2018, 06-01, Volume: 124, Issue:11 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Ascorbic Acid; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Disease-Free Survival; Female; Headache; Hematopoietic Stem Cell Transplantation; Hong Kong; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Risk Factors; Severity of Illness Index; Survival Analysis; Time Factors; Transplantation, Autologous; Tretinoin; Young Adult	2018
Synergistic effect of arsenic trioxide, vismodegib and temozolomide on glioblastoma. Oncology reports, 2019, Volume: 41, Issue:6 Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Neoplasm Recurrence, Local; Pyridines; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays	2019
Acute promyelocytic leukemia with Flt3-TKD and WT1 mutations relapsing in a testicle and followed by systemic relapse. Acta haematologica, 2013, Volume: 130, Issue:4 Topics: Adult; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Daunorubicin; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Salvage Therapy; Sarcoma, Myeloid; Testicular Neoplasms; Testis; Tretinoin; WT1 Proteins	2013
Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells. Oncogene, 2014, Nov-13, Volume: 33, Issue:46 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blotting, Western; Bone Marrow Transplantation; Core Binding Factor Alpha 2 Subunit; Disease Models, Animal; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Mice, Inbred C57BL; Mice, Transgenic; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Oxides; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome	2014
Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model. Journal of hematology & oncology, 2014, Mar-30, Volume: 7 Topics: AC133 Antigen; Animals; Antigens, CD; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Differentiation; Cell Line, Tumor; Disease Models, Animal; Down-Regulation; Glycoproteins; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Oxides; Peptides; Random Allocation; Signal Transduction; Survival Analysis; Transcription Factors; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1	2014
ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia. PloS one, 2014, Volume: 9, Issue:8 Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin; Young Adult	2014
Induction, consolidation, and maintenance therapies with arsenic as a single agent for acute promyelocytic leukaemia in a 11-year follow-up. Hematological oncology, 2017, Volume: 35, Issue:1 Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Remission Induction; Time Factors; Treatment Outcome; Young Adult	2017
Targeting hedgehog signalling by arsenic trioxide reduces cell growth and induces apoptosis in rhabdomyosarcoma. International journal of oncology, 2016, Volume: 48, Issue:2 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Hedgehog Proteins; Humans; Itraconazole; Muscle Cells; Muscle, Skeletal; Neoplasm Recurrence, Local; Oxides; Rhabdomyosarcoma; Signal Transduction; Transcription Factors	2016
[Relapse of acute promyelocytic leukemia in the central nervous system revealed by isolated dementia]. La Revue de medecine interne, 2016, Volume: 37, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Dementia; Female; Humans; Leukemia, Promyelocytic, Acute; Meningeal Neoplasms; Neoplasm Recurrence, Local; Oxides; Recurrence; Remission Induction	2016
PHA-Induced Peripheral Blood Cytogenetics and Molecular Analysis: a Valid Diagnostic and Follow-up Modality for Acute Promyelocytic Leukemia Patients Treated with ATRA and/or Arsenic Tri-oxide. Asian Pacific journal of cancer prevention : APJCP, 2016, Volume: 17, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blood Cells; Child; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytogenetic Analysis; Female; Follow-Up Studies; Gene Rearrangement; Humans; In Situ Hybridization, Fluorescence; India; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oncogene Proteins, Fusion; Oxides; Phytohemagglutinins; Prognosis; Translocation, Genetic; Tretinoin	2016
Delayed hematological recovery following autologous transplantation utilizing peripheral blood stem cells harvested after treatment with arsenic trioxide. Pathology oncology research : POR, 2008, Volume: 14, Issue:4 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Peripheral Blood Stem Cell Transplantation; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Autologous	2008
Curative strategies in acute promyelocytic leukemia. Hematology. American Society of Hematology. Education Program, 2008 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Cytarabine; Daunorubicin; Disease-Free Survival; Growth Inhibitors; History, 20th Century; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasm Recurrence, Local; Oxides; Tretinoin	2008
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-01, Volume: 27, Issue:22 Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Blood Chemical Analysis; Bone Marrow; Cohort Studies; Confidence Intervals; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Monitoring, Physiologic; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Predictive Value of Tests; Probability; Prognosis; Proportional Hazards Models; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Severity of Illness Index; Survival Analysis; Treatment Outcome; Tretinoin	2009
External auditory canal and middle ear relapse of acute promyelocytic leukemia treated with arsenic trioxide: case report and review of the literature. Journal of pediatric hematology/oncology, 2010, Volume: 32, Issue:3 Topics: Arsenic Trioxide; Arsenicals; Child; Ear Canal; Ear Neoplasms; Ear, Middle; Female; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Treatment Outcome	2010
Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. International journal of radiation oncology, biology, physics, 2011, Jan-01, Volume: 79, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxides; Radiotherapy Planning, Computer-Assisted; Temozolomide; Tomography, X-Ray Computed; Treatment Failure; Tumor Burden; Young Adult	2011
5-Fluorouracil/Leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma: a clinical experience. Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Treatment Outcome	2011
[A successful case of tanshinone II A treatment for relapsed acute promyelocytic leukemia after maintainance therapy of all-trans retinoic acid and arsenic trioxide]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2010, Volume: 41, Issue:6 Topics: Abietanes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Neoplasm Recurrence, Local; Oxides; Tretinoin; Young Adult	2010
Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran. Archives of Iranian medicine, 2011, Volume: 14, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Cohort Studies; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Iran; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult	2011
Characterization of arsenic-induced cytogenetic alterations in acute promyelocytic leukemia cell line, NB4. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Chromosome Aberrations; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Tumor Cells, Cultured	2012
Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood, 2011, Aug-11, Volume: 118, Issue:6 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Binding Sites; Cytoplasm; Drug Resistance, Neoplasm; Female; HeLa Cells; Humans; Immunoblotting; Leukemia, Promyelocytic, Acute; Male; Microscopy, Fluorescence; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Sumoylation; Transcription Factors; Transcription, Genetic; Tumor Suppressor Proteins; U937 Cells; Young Adult	2011
Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient. Journal of hematology & oncology, 2012, Jan-24, Volume: 5 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Humans; Leukemia, Promyelocytic, Acute; Mass Spectrometry; Middle Aged; Neoplasm Recurrence, Local; Oxides; Prognosis; Remission Induction; Salvage Therapy; Tissue Distribution	2012
Arsenic trioxide: expanding roles for an ancient drug? Leukemia, 2004, Volume: 18, Issue:9 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oxides; Salvage Therapy	2004
A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia, 2004, Volume: 18, Issue:9 Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oxides; Salvage Therapy	2004
Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Prognosis; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate; Treatment Outcome	2006
[Oral administration of arsenic trioxide induced molecular remission in relapsed acute promyelocytic leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2005, Volume: 46, Issue:11 Topics: Administration, Oral; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Remission Induction	2005
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer, 2007, Apr-01, Volume: 109, Issue:7 Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Treatment Outcome; Tretinoin	2007
Acute intestinal pseudo-obstruction after induction treatment of relapsed acute promyelocytic leukemia with arsenic trioxide. Pediatric blood & cancer, 2008, Volume: 50, Issue:4 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Digestive System Surgical Procedures; Female; Humans; Intestinal Pseudo-Obstruction; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides	2008
Arsenic trioxide entered cerebrospinal fluid with the help of mannitol overwhelm the meningeal relapse of acute promyelocytic leukemia. Haematologica, 2007, Volume: 92, Issue:9 Topics: Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Female; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Magnetic Resonance Imaging; Mannitol; Meningeal Neoplasms; Neoplasm Recurrence, Local; Oxides; Remission Induction	2007
[Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2000, Volume: 41, Issue:4 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Pleural Effusion; Remission Induction; Treatment Outcome; Tretinoin	2000
Arsenic trioxide treatment of relapsed acute promyelocytic leukaemia: initial Australian experience. Australian and New Zealand journal of medicine, 1999, Volume: 29, Issue:3 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Australia; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides	1999
Long-term survey of outcome in acute promyelocytic leukemia. Chinese medical journal, 2000, Volume: 113, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Prognosis; Remission Induction; Time Factors; Treatment Outcome; Tretinoin	2000